How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,726 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children

Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children More than 1 in 10 HIV-related deaths are as a result of cryptococcal me n i n g i t i s. Three quarters of deaths from cryptococcal meningitis are in sub-Saharan Africa. WHO/CDS/HIV/18.2 POLICY BRIEF WHO / James Oatway: Namibia Living with HIV / AIDS at the Katatura State Hospital in Windhoek, Namibia. GUIDELINES FOR THE DIAGNOSIS, PREVENTION AND MANAGEMENT (...) OF CRYPTOCOCCAL DISEASE IN HIV-INFECTED ADULTS, ADOLESCENTS AND CHILDREN SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION MARCH 2018 HIV TREATMENT 1 Cryptococcal meningitis is by far the commonest manifestation of cryptococcal disease representing 70–90% of HIV-related cryptococcal disease. Other less common disease presentations include pulmonary disease and skin, lymph node and bone involvement. The burden of morbidity and mortality

2018 World Health Organisation HIV Guidelines

62. Short-course antiretroviral therapy in primary HIV infection. (PubMed)

Short-course antiretroviral therapy in primary HIV infection. Short-course antiretroviral therapy (ART) in primary human immunodeficiency virus (HIV) infection may delay disease progression but has not been adequately evaluated.We randomly assigned adults with primary HIV infection to ART for 48 weeks, ART for 12 weeks, or no ART (standard of care), with treatment initiated within 6 months after seroconversion. The primary end point was a CD4+ count of less than 350 cells per cubic millimeter (...) a greater interval between ART initiation and the primary end point the closer that ART was initiated to estimated seroconversion (P=0.09), and 48-week ART conferred a reduction in the HIV RNA level of 0.44 log(10) copies per milliliter (95% CI, 0.25 to 0.64) 36 weeks after the completion of short-course therapy. There were no significant between-group differences in the incidence of the acquired immunodeficiency syndrome, death, or serious adverse events.A 48-week course of ART in patients with primary

Full Text available with Trip Pro

2013 NEJM

63. An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials

An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2017 Clinical Trials

64. Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. (PubMed)

no effects were seen on plasma markers of inflammation or tryptophan metabolism. No significant immunological effects of etoricoxib were observed in ART-treated patients. Patients receiving long-term etoricoxib treatment had poorer tetanus toxoid and conjugated pneumococcal vaccine responses than those receiving short-course etoricoxib. Cyclooxygenase-2 inhibitors may attenuate harmful immune activation in HIV-infected patients without access to ART. (...) Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. Pathologically elevated immune activation and inflammation contribute to HIV disease progression and immunodeficiency, potentially mediated by elevated levels of prostaglandin E2, which suppress HIV-specific T cell responses. We have previously shown that a high dose of the cyclooxygenase-2 inhibitor celecoxib can reduce HIV

Full Text available with Trip Pro

2017 PLoS ONE

65. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children

Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children SUPPLEMENT GUIDELINES ON POST-EXPOSURE PROPHYLAXIS FOR HIV AND THE USE OF CO-TRIMOXAZOLE PROPHYLAXIS FOR HIV-RELATED INFECTIONS AMONG ADULTS, ADOLESCENTS AND CHILDREN: RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH DECEMBER 2014 SUPPLEMENT TO THE 2013 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV (...) INFECTIONSUPPLEMENT GUIDELINES ON POST-EXPOSURE PROPHYLAXIS FOR HIV AND THE USE OF CO-TRIMOXAZOLE PROPHYLAXIS FOR HIV-RELATED INFECTIONS AMONG ADULTS, ADOLESCENTS AND CHILDREN: RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH DECEMBER 2014 SUPPLEMENT TO THE 2013 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTIONWHO Library Cataloguing-in-Publication Data : Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related

2015 World Health Organisation HIV Guidelines

66. Consolidated guidelines on person-centred HIV patient monitoring and case surveillance

Consolidated guidelines on person-centred HIV patient monitoring and case surveillance CONSOLIDATED GUIDELINES ON PERSON-CENTRED HIV PATIENT MONITORING AND CASE SURVEILLANCE JUNE 2017 GUIDELINES HIV STRATEGIC INFORMATION FOR IMPACTCONSOLIDATED GUIDELINES ON PERSON-CENTRED HIV PATIENT MONITORING AND CASE SURVEILLANCE JUNE 2017Consolidated guidelines on person-centred HIV patient monitoring and case surveillance ISBN 978-92-4-151263-3 © World Health Organization 2017 Some rights reserved (...) the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Consolidated guidelines on person-centred HIV patient monitoring and case surveillance. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests

2017 World Health Organisation HIV Guidelines

67. Guidelines on the public health response to pretreatment HIV drug resistance

Guidelines on the public health response to pretreatment HIV drug resistance Introduction i GUIDELINES GUIDELINES ON THE PUBLIC HEALTH RESPONSE TO PRETREATMENT HIV DRUG RESISTANCE JULY 2017 HIV DRUG RESISTANCEGUIDELINES ON JULY 2017 THE PUBLIC HEALTH RESPONSE TO PRETREATMENT HIV DRUG RESISTANCEGuidelines on the public health response to pretreatment HIV drug resistance: July 201 7 ISBN 978-92-4-155005-5 © World Health Organization 2017 Some rights reserved. This work is available under (...) in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Guidelines on the public health response to pretreatment HIV drug resistance, July 201 7 . Geneva: World Health Organization; 201 7 . Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/ bookorders. To submit requests for commercial use and queries

2017 World Health Organisation HIV Guidelines

68. Individual support of nurses using electronic medicine monitors can improve HIV treatment

routine clinic visits. We did mixed-effects, intent-to-treat analyses to examine treatment effects on the primary outcome of log10 viral load collected at months 5, 10, and 15. The viral load results were exponentiated (with base 10) for easier interpretation. Using cohort data from 7347 Dutch patients with HIV to calculate the natural course of illness, we developed a lifetime Markov model to estimate the primary economic outcome of lifetime societal costs per quality-adjusted life-years (QALYs (...) Individual support of nurses using electronic medicine monitors can improve HIV treatment Individual support of nurses using electronic medicine monitors can improve HIV treatment Discover Portal Discover Portal Individual support of nurses using electronic medicine monitors can improve HIV treatment Published on 10 October 2017 doi: Use of electronic pill bottles that record when they are opened and follow-up discussion of the printed readouts with nurses improved HIV outcomes. It is thought

2019 NIHR Dissemination Centre

69. Consolidated guideline on sexual and reproductive health and rights of women living with HIV

(Department of Reproductive Health and Research [RHR]), Rachel Baggaley (Department of HIV/ AIDS), John Beard (Department of Ageing and Life Course [ALC]), Ana Pilar Betrán Lazaga (Department of RHR), Francoise Bigirimana (WHO Regional Office for Africa), Sonja Caffe (WHO Regional Office for the Americas/Pan American Health Organization [PAHO]), Rebekah Bosco Thomas (Gender, Equity and Human Rights T eam), Nathalie Broutet (Department of RHR), T arun Dua (Department of Mental Health and Substance Abuse (...) of evidence Healthy sexuality across the life course REC A.1: Adolescent-friendly health services should be implemented in HIV services to ensure engagement and improved outcomes. 1 Strong recommendation, low- quality evidence Integration of SRHR and HIV services REC A.2: In generalized epidemic settings, antiretroviral therapy (ART) should be initiated and maintained in eligible pregnant and postpartum women and in infants at maternal and child health care settings, with linkage and referral to ongoing

2017 World Health Organisation Guidelines

70. Consolidated guideline on sexual and reproductive health and rights of women living with HIV

health and rights of women living with HIV 4 Table 1: Summary list of WHO recommendations for the sexual and reproductive health and rights (SRHR) of women living with HIV Note: Where recommendations apply to “key populations” this includes women living with HIV and therefore these have been included in these guidelines. A. Creating an enabling environment Recommendation (REC) Strength of recommendation, quality of evidence Healthy sexuality across the life course REC A.1: Adolescent-friendly health (...) ) Psychosocial support GPS A.1 (NEW): Psychosocial support interventions, such as support groups and peer support, provided by, with, and for women living with HIV, should be included in HIV care. Healthy sexuality across the life course GPS A.2 (NEW): Women living with HIV in all their diversity should be supported in their choice to have safe and fulfilling sexual relationships and sexual pleasure as they age. Women living with HIV who choose not to be sexually active should also be supported

2017 World Health Organisation Guidelines

71. Improving healthcare providers? face-to-face interactions with clients living with or at-risk for HIV

) – in particular, the user’s health literacy level. Health literacy is “the ability to access, understand, evaluate and communicate information as a way to promote, maintain and improve health in a variety of settings across the life-course” (13). More than half of Canadians do not meet the minimum literacy requirements to manage their health needs (14). For persons at higher risk of HIV, and for those already living with HIV, poor health literacy interferes with their ability to fully understand HIV risk (...) Improving healthcare providers? face-to-face interactions with clients living with or at-risk for HIV RAPID RESPONSE SERVICE | #111, AUGUST 2016 1 RAPID RESPONSE SERVICE THE ONTARIO HIV TREATMENT NETWORK Question • What face-to-face interventions have proven effective in helping providers educate clients and improve their health literacy? References 1. Price-Haywood EG, Harden- Barrios J, Cooper LA. Comparative effectiveness of audit-feedback versus additional physician communication training

2016 Ontario HIV Treatment Network

72. HIV and STI testing among Indigenous women and women who inject drugs

provided HIV testing and pre- and post-test counselling. Women’s- only needle exchange services were also provided at workshops whenever possible. Participants received grocery store gift cards for being tested, for returning for STI and HIV test results, and for attending each of the four educational workshops (10). Over the course of three years, the WORKS intervention engaged 562 participants – 68% of whom were current or former injection drug users. HIV and STI testing rates were high (...) HIV and STI testing among Indigenous women and women who inject drugs RAPID RESPONSE SERVICE | #105, MAY 2016 1 Questions What programs and services have been shown to be effective in increasing HIV and STI testing among Indigenous women and women who inject drugs? References 1. Orchard TR, Druyts E, McInnes CW , Clement K, Ding E, Fernandes KA et al. Factors behind HIV testing practices among Canadian Aboriginal peoples living off-reserve. AIDS Care 2010 March;22(3):324-31. 2. Lally MA

2016 Ontario HIV Treatment Network

73. Antenatal screening approaches effective in preventing MTCT of HIV, HBV, syphilis and rubella in vulnerable populations

Antenatal screening approaches effective in preventing MTCT of HIV, HBV, syphilis and rubella in vulnerable populations TECHNICAL REPORT Antenatal screening approaches effective in preventing mother- child-transmission of HIV, hepatitis B, syphilis and rubella in vulnerable populations Literature review www.ecdc.europa.euECDC TECHNICAL REPORT Antenatal screening approaches effective in preventing mother-to-child transmission of HIV, hepatitis B, syphilis and rubella in vulnerable populations (...) Leino, Markku Kuusi, and Mika Salminen Helena de Carvalho Gomes and Ana-Belen Escriva are acknowledged for internal ECDC support. Suggested citation: European Centre for Disease Prevention and Control. Antenatal screening approaches effective in preventing mother-child-transmission of HIV, hepatitis B, syphilis and rubella in vulnerable populations. Stockholm: ECDC; 2017. Stockholm, March 2017 ISBN 978-92-9498-032-8 doi: 10.2900/580446 Catalogue number TQ-02-17-142-EN-N © European Centre for Disease

2017 European Centre for Disease Prevention and Control - Literature Reviews

74. Communication strategies for the prevention of HIV, STI and hepatitis among MSM in Europe

) may promote risk taking and undermine established social norms. However, over the course of the HIV epidemic, evidence points in a different direction. Many new and successful prevention strategies were developed in the MSM community; condom use among MSM increased as soon as AIDS was linked to sex, and AIDS activists promoted the practice through their networks. The concept of ‘negotiated safety’ also originated in the MSM community, long before the concept was given a name, defined and promoted (...) Communication strategies for the prevention of HIV, STI and hepatitis among MSM in Europe www.ecdc.europa.eu Communication strategies for the prevention of HIV, STI and hepatitis among MSM in Europe TECHNICAL DOCUMENT ECDC TECHNICAL DOCUMENT Communication strategies for the prevention of HIV, STIs and hepatitis among MSM in Europe ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Irina Dinca, Piotr Wysocki, Anastasia Pharris

2016 European Centre for Disease Prevention and Control - Technical Guidance

75. Intermittent Courses of Corticosteroids Also Present a Risk for Pneumocystis Pneumonia in Non-HIV Patients (PubMed)

Intermittent Courses of Corticosteroids Also Present a Risk for Pneumocystis Pneumonia in Non-HIV Patients Introduction. Pneumocystis pneumonia (PCP) is rising in the non-HIV population and associates with higher morbidity and mortality. The aggressive immunosuppressive regimens, as well as the lack of stablished guidelines for chemoprophylaxis, are likely contributors to this increased incidence. Herein, we have explored the underlying conditions, immunosuppressive therapies, and clinical (...) outcomes of PCP in HIV-negative patients. Methods. Retrospective analysis of PCP in HIV-negative patients at Mayo Clinic from 2006-2010. The underlying condition, immunosuppressive therapies, coinfection, and clinical course were determined. PCP diagnosis required symptoms of pneumonia and identification of the organisms by visualization or by a real-time polymerase chain reaction. Results. A total of 128 cases of PCP were identified during the study period. Hematological malignancies were

Full Text available with Trip Pro

2016 Canadian respiratory journal

76. HIV and adolescents: Guidance for HIV testing and counselling and care for adolescents living with HIV

HIV and adolescents: Guidance for HIV testing and counselling and care for adolescents living with HIV RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH AND CONSIDERATIONS FOR POLICY-MAKERS AND MANAGERS HIV AND ADOLESCENTS: GUIDANCE FOR HIV TESTING AND COUNSELLING AND CARE FOR ADOLESCENTS LIVING WITH HIV United Nations Educational, Scienti?c and Cultural Organization ISBN 978 92 4 150616 8 HIV AND ADOLESCENTS: GUIDANCE FOR HIV TESTING AND COUNSELLING AND CARE FOR ADOLESCENTS LIVING WITH HIV ? World (...) Health Organization 20, avenue Appia CH–1211 Geneva 27 Switzerland For more information, contact: ? Department of HIV/AIDS E-mail: hiv-aids@who.int http://www.who.int/hiv/en/ ? Department of Maternal, Newborn, Child and Adolescent Health Email: mncah@who.int http://www.who.int/maternal_child_adolescent/en/RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH AND CONSIDERATIONS FOR POLICY-MAKERS AND MANAGERS HIV AND ADOLESCENTS: GUIDANCE FOR HIV TESTING AND COUNSELLING AND CARE FOR ADOLESCENTS LIVING

2013 World Health Organisation HIV Guidelines

77. Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics???

Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? | BMJ EBM Spotlight by A recent BMJ analysis article argued that taking the “full course of antibiotics” is often likely counterproductive (see doi: 10.1136/bmj.j3418 )​. Details: –international health organizations and the WHO have pushed for completing antibiotic regimens: a 2016 WHO advisory to patients stated “always complete (...) the full prescription, even if you feel better, because stopping treatment early promotes the growth of drug-resistant bacteria”. The CDC has a similar message –the authors note that there is impressive evidence that some micro-organisms (eg TB, gonorrhea, HIV, S. typhi) can create spontaneous resistant mutations on treatment, and these mutants subsequently can be transmitted as resistant strains. [and there are good data supporting longer term therapies] –but many of the organisms with growing

2017 Evidence-Based Medicine blog

78. Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics???

Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? | BMJ EBM Spotlight by A recent BMJ analysis article argued that taking the “full course of antibiotics” is often likely counterproductive (see doi: 10.1136/bmj.j3418 )​. Details: –international health organizations and the WHO have pushed for completing antibiotic regimens: a 2016 WHO advisory to patients stated “always complete (...) the full prescription, even if you feel better, because stopping treatment early promotes the growth of drug-resistant bacteria”. The CDC has a similar message –the authors note that there is impressive evidence that some micro-organisms (eg TB, gonorrhea, HIV, S. typhi) can create spontaneous resistant mutations on treatment, and these mutants subsequently can be transmitted as resistant strains. [and there are good data supporting longer term therapies] –but many of the organisms with growing

2017 Evidence-Based Medicine blog

79. HIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

, the DSMB recommended that all study participants should be offered study drug. A total of 23 participants became infected with HIV over the course of the study: three in the daily TDF-FTC group and 20 in the deferred (no-PrEP) group, representing a rate difference in HIV infection of 7.8 per 100 person-years (90% CI 4.3–11.3) The relative risk reduction was 86% (90% CI 64–96%) and the number needed to treat over 1 year to prevent one HIV infection was 13 (90% CI 9–23). BHIVA/BASHH guidelines on the use (...) followed up every 8 weeks for HIV testing and risk-reduction advice, and every 6 months for sexually transmitted infection (STI) testing for a total of 431 person-years of follow-up. Primary endpoint was HIV infection. At interim review, the placebo group was discontinued and all study participants were offered study drug. Over the course of the study, 16 people became infected with HIV: two in the TDF-FTC group and 14 in the placebo group, representing a relative risk reduction of 86% (95% CI 40–98

2018 British HIV Association

80. Fatal Disseminated Kaposi’s Sarcoma in Two Patients with Human Immunodeficiency Virus (HIV) Infection Fatal Disseminated Kaposi’s Sarcoma in Two Patients with Human Immunodeficiency Virus (HIV) Infection (PubMed)

and disseminated KS is presented in two patients with HIV/AIDS. CASE REPORT A 25-year-old man and a 30-year-old man with HIV/AIDS presented with KS affecting the skin, oral cavity, gastrointestinal tract, liver, lungs, kidneys, adrenal glands, and bone. Both patients had a rapidly deteriorating clinical course associated with a low CD4 count and developed respiratory failure and death. CONCLUSIONS Fatal disseminated KS is associated with severe immunosuppression due to with a low CD4 count. The presentation (...) of these two cases highlights the potentially aggressive clinical course of KS in patients with HIV/AIDS and reinforces the need for early diagnosis and rapid treatment with HAART.

Full Text available with Trip Pro

2018 The American journal of case reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>